Literature DB >> 9840138

Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.

K Soga1, T Watanabe, K Aikawa, M Toshima, K Shibasaki, Y Aoyagi.   

Abstract

BACKGROUND/AIMS: In the diagnosis of hepatocellular carcinoma (HCC), serum des-gamma-carboxyprothrombin (DCP) is a useful tumor marker. The conventional immunoassays for measurement of DCP levels, however, are not sensitive enough to detect small HCC. Therefore, we intended to elevate the minimal detection level of DCP by a modified enzyme linked immunosorbent assay method.
METHODOLOGY: This modified assay method is similar to the conventional enzyme linked immunosorbent assay (ELISA) method, but the first reaction occurs overnight. As a result, the minimal detection levels of DCP varied from 0.06 AU/ml, by the conventional method, to 0.008 AU/ml, by the modified method. Two hundred and twenty five serum samples from 100 patients with HCC, 75 with liver cirrhosis and 50 with chronic hepatitis were subjected to the present study. Simultaneous determinations of serum DCP by the modified assay and a-fetoprotein (AFP) levels were performed.
RESULTS: Eighty five of 100 patients with HCC had increased DCP levels of more than 0.008 AU/ml. This method yielded a sensitivity of 85%, a specificity of 90% and a total accuracy value of 88%. In 27 patients with small HCC (less than 30 mm in diameter), 12 had elevated DCP levels, resulting in a sensitivity of 44%. When the modified DCP assay together with AFP measurement (more than 20 ng/ml) were introduced, the sensitivity was 67% in the 27 patients with small HCC.
CONCLUSIONS: This modified ELISA method increased the sensitivity in patients with small HCC, and the combination assay of serum DCP and AFP levels was more useful for the early diagnosis of HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840138

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.

Authors:  Li Jiang; Xue Li; Qi Cheng; Bin-Hao Zhang
Journal:  Tumour Biol       Date:  2015-04-17

2.  Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients.

Authors:  Moemen Ak Abdalla; Yousef Haj-Ahmad
Journal:  J Cancer       Date:  2011-12-09       Impact factor: 4.207

3.  Identification of serum CCL15 in hepatocellular carcinoma.

Authors:  Y Li; J Wu; W Zhang; N Zhang; H Guo
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

4.  The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma.

Authors:  Asako Kimura; Kazuyuki Sogawa; Mamoru Satoh; Yoshio Kodera; Osamu Yokosuka; Takeshi Tomonaga; Fumio Nomura
Journal:  Int J Proteomics       Date:  2012-08-16

5.  Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients.

Authors:  Moemen Ak Abdalla; Yousef Haj-Ahmad
Journal:  J Cancer       Date:  2012-09-18       Impact factor: 4.207

6.  Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach.

Authors:  Min He; Jian Qin; Rihong Zhai; Xiao Wei; Qi Wang; Minhua Rong; Zhihua Jiang; Yuanjiao Huang; Zhiyong Zhang
Journal:  Proteome Sci       Date:  2008-03-10       Impact factor: 2.480

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.